Finding hope by expanding the frontiers of therapy
We design ground-breaking therapies through precision-targeting of membrane receptors to bring hope to people living with autoimmune diseases
Latest News
Two key experts joining us to accelerate the development of FTX-101
We’re pleased to welcome Dr. Nancy Messier and Dr. Thierry Abribat to our Board of…
FTX-101 Phase 1 Clinical Trial Launched
First Subject Dosed with FTX-101. This study marks the beginning of a journey toward a…
Investissement Québec supports Find Therapeutics
Find Therapeutics today announced the closing of a $8.1 million (CAD$11 million) convertible note financing…